These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Germline Mutational Landscape and Novel Targetable Feng Z; Chen S; An N; Xiu Z; Ju X; Chen X; Bi R; Wang J; Zhu S; Wu X; Wen H JCO Glob Oncol; 2024 Jun; 10():e2300454. PubMed ID: 38905575 [TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics and survival analysis of Chinese ovarian cancer patients with RAD51D germline mutations. Yao H; Li N; Yuan H BMC Cancer; 2022 Dec; 22(1):1337. PubMed ID: 36544182 [TBL] [Abstract][Full Text] [Related]
5. Associations between RAD51D germline mutations and breast cancer risk and survival in BRCA1/2-negative breast cancers. Chen X; Li Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y Ann Oncol; 2018 Oct; 29(10):2046-2051. PubMed ID: 30165555 [TBL] [Abstract][Full Text] [Related]
6. Germline mutations in RAD51C and RAD51D and hereditary predisposition to ovarian cancer. Soukupová J; Lhotová K; Janatová M; Kleiblová P; Vočka M; Foretová L; Zikán M; Kleibl Z Klin Onkol; 2021; 34(1):26-32. PubMed ID: 33657816 [TBL] [Abstract][Full Text] [Related]
7. Optimization of prediction methods for risk assessment of pathogenic germline variants in the Japanese population. Senda N; Kawaguchi-Sakita N; Kawashima M; Inagaki-Kawata Y; Yoshida K; Takada M; Kataoka M; Torii M; Nishimura T; Kawaguchi K; Suzuki E; Kataoka Y; Matsumoto Y; Yoshibayashi H; Yamagami K; Tsuyuki S; Takahara S; Yamauchi A; Shinkura N; Kato H; Moriguchi Y; Okamura R; Kan N; Suwa H; Sakata S; Mashima S; Yotsumoto F; Tachibana T; Tanaka M; Togashi K; Haga H; Yamada T; Kosugi S; Inamoto T; Sugimoto M; Ogawa S; Toi M Cancer Sci; 2021 Aug; 112(8):3338-3348. PubMed ID: 34036661 [TBL] [Abstract][Full Text] [Related]
8. Contribution of RAD51D germline mutations in breast and ovarian cancer in Greece. Konstanta I; Fostira F; Apostolou P; Stratikos E; Kalfakakou D; Pampanos A; Kollia P; Papadimitriou C; Konstantopoulou I; Yannoukakos D J Hum Genet; 2018 Nov; 63(11):1149-1158. PubMed ID: 30111881 [TBL] [Abstract][Full Text] [Related]
9. Germline mutation in the RAD51B gene confers predisposition to breast cancer. Golmard L; Caux-Moncoutier V; Davy G; Al Ageeli E; Poirot B; Tirapo C; Michaux D; Barbaroux C; d'Enghien CD; Nicolas A; Castéra L; Sastre-Garau X; Stern MH; Houdayer C; Stoppa-Lyonnet D BMC Cancer; 2013 Oct; 13():484. PubMed ID: 24139550 [TBL] [Abstract][Full Text] [Related]
10. Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D. Yang X; Song H; Leslie G; Engel C; Hahnen E; Auber B; Horváth J; Kast K; Niederacher D; Turnbull C; Houlston R; Hanson H; Loveday C; Dolinsky JS; LaDuca H; Ramus SJ; Menon U; Rosenthal AN; Jacobs I; Gayther SA; Dicks E; Nevanlinna H; Aittomäki K; Pelttari LM; Ehrencrona H; Borg Å; Kvist A; Rivera B; Hansen TVO; Djursby M; Lee A; Dennis J; Bowtell DD; Traficante N; Diez O; Balmaña J; Gruber SB; Chenevix-Trench G; Investigators K; Jensen A; Kjær SK; Høgdall E; Castéra L; Garber J; Janavicius R; Osorio A; Golmard L; Vega A; Couch FJ; Robson M; Gronwald J; Domchek SM; Culver JO; de la Hoya M; Easton DF; Foulkes WD; Tischkowitz M; Meindl A; Schmutzler RK; Pharoah PDP; Antoniou AC J Natl Cancer Inst; 2020 Dec; 112(12):1242-1250. PubMed ID: 32107557 [TBL] [Abstract][Full Text] [Related]
11. Loss of function germline mutations in RAD51D in women with ovarian carcinoma. Wickramanayake A; Bernier G; Pennil C; Casadei S; Agnew KJ; Stray SM; Mandell J; Garcia RL; Walsh T; King MC; Swisher EM Gynecol Oncol; 2012 Dec; 127(3):552-5. PubMed ID: 22986143 [TBL] [Abstract][Full Text] [Related]
13. Germline Kwong A; Ho CYS; Au CH; Tey SK; Ma ESK J Pers Med; 2024 Aug; 14(8):. PubMed ID: 39202057 [TBL] [Abstract][Full Text] [Related]
14. Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer. Torres-Esquius S; Llop-Guevara A; Gutiérrez-Enríquez S; Romey M; Teulé À; Llort G; Herrero A; Sánchez-Henarejos P; Vallmajó A; González-Santiago S; Chirivella I; Cano JM; Graña B; Simonetti S; Díaz de Corcuera I; Ramon Y Cajal T; Sanz J; Serrano S; Otero A; Churruca C; Sánchez-Heras AB; Servitja S; Guillén-Ponce C; Brunet J; Denkert C; Serra V; Balmaña J JAMA Netw Open; 2024 Apr; 7(4):e247811. PubMed ID: 38648056 [TBL] [Abstract][Full Text] [Related]
15. About 1% of the breast and ovarian Spanish families testing negative for BRCA1 and BRCA2 are carriers of RAD51D pathogenic variants. Gutiérrez-Enríquez S; Bonache S; de Garibay GR; Osorio A; Santamariña M; Ramón y Cajal T; Esteban-Cardeñosa E; Tenés A; Yanowsky K; Barroso A; Montalban G; Blanco A; Cornet M; Gadea N; Infante M; Caldés T; Díaz-Rubio E; Balmaña J; Lasa A; Vega A; Benítez J; de la Hoya M; Diez O Int J Cancer; 2014 May; 134(9):2088-97. PubMed ID: 24130102 [TBL] [Abstract][Full Text] [Related]